METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
|Articles|September 22, 2016
EpiPen Controversy: Mylan CEO Faces Congressional Committee
Author(s)Pharmaceutical Technology
September 22, 2016
Advertisement
Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.
In her
For the rest of this news release, see
Advertisement
Related to this article
PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Advertisement
Advertisement
Trending on PharmExec
1
METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies
2
How MFN Deals May Impact Future Decisions
3
Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion
4
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli
5